Pomalidomide Ixazomib and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    Feb 25, 2022
  • participants needed
    82
  • sponsor
    GWT-TUD GmbH
Updated on 25 January 2021
platelet count
cyclophosphamide
cell transplantation
dexamethasone
lenalidomide
neutrophil count
bortezomib
alkylating agents
ixazomib
pomalidomide

Summary

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in the study. After the first 6 patients will have finished the first treatment cycle of the induction phase the DMC will assess safety and tolerability of the treatment schedule and decide about the further continuation of the study.

Description

The study is designed as an open-label, non-randomized, multicenter study to investigate the clinical activity of pomalidomide administered once daily in combination with oral ixazomib and dexamethasone (PId) until disease progression according to IMWG criteria.

Patients with clinical relapse (any one of the following: deterioration of renal function, hypercalcemia, newly developing osteolytic lesions and/or soft tissue plasmacytomas) will go off study and receive further treatment according to their treating physician. Patients with isolated biochemical relapse with an increase of serum M-protein of 25% (absolute increase in serum must be 5 g/L) and/or urine M-protein (absolute increase in urine must be 200 mg/24h) or in the difference between involved and uninvolved FLC levels (provided, the absolute increase is > 100 mg/L) without further signs or symptoms will proceed to the intensification phase (PICd).

The intensification phase (PICd) will last until further disease progression. In case of significant haematological and non-haematological toxicities, dose adjustments and/or interruption of the study drugs may be necessary.

Response assessments will be performed every four weeks by evaluation of serum and 24 hour urine specimens. "Progressive disease" (PD) will require a consecutive confirmatory measurement.

Details
Condition Refractory Multiple Myeloma
Treatment cyclophosphamide, Dexamethasone, MLN9708, Pomalidomide 4 MG Oral Capsule
Clinical Study IdentifierNCT03731832
SponsorGWT-TUD GmbH
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Refractory Multiple Myeloma?
Do you have any of these conditions: Do you have Refractory Multiple Myeloma??
Male or female patients 18 years of age at the time of signing the informed consent form
Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study has been obtained prior to any study related assessments/ procedures being conducted
Patients with relapsed or refractory, histologically confirmed multiple myeloma
Patients must have received at least two but not more than four prior anti-myeloma regimens including lenalidomide and bortezomib and have demonstrated disease progression on the last therapy
Prior treatments must have included both lenalidomide and bortezomib: at least two consecutive cycles of lenalidomide and bortezomib (alone or in combination) and adequate prior alkylator exposure. This is either as part of a stem cell transplant or at least 6 consecutive cycles of an alkylator-based therapy
Patients must have failed bortezomib and lenalidomide therapy: progression within 60 days; PR or better with progression within 6 month and/or bortezomib intolerant after 2 cycles and achieving MR
Relapsed from or refractory to at least one regimen (induction, autologous stem cell transplantation (or allogenic stem cell transplantation) and consolidation/maintenance are considered one "regimen")
Measurable levels of serum and/or urine M-protein: serum M-protein 5 g/L and/or urine M-protein 200 mg/24h or serum free light chain (sFLC) concentration of > 100 mg/L of the involved FLC, provided sFLC ratio is abnormal (sFLC K/ ratio (< 0.26 or > 1.65)
Life expectancy 3 months
ECOG performance status of 0, 1, or 2
Patients must be able to adhere to the study visit schedule and other protocol requirements
All women and men must acknowledge to have understood the hazards and necessary precautions associated with the use of pomalidomide and ixazomib
All subjects must agree in writing to strictly adhere to the Pomalidomide Pregnancy Prevention Plan as given in Appendix C
Females of childbearing potential (FCBP) must
Understand the potential teratogenic risk to the unborn child
Agree to utilize two reliable forms of contraception simultaneously without interruption for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 90 days after study treatment discontinuation
Be capable of complying with effective contraceptive measures
Be informed and understand the potential consequences of pregnancy and the need to notify her study doctor immediately if there is a risk of pregnancy
Understand the need to commence the study treatment as soon as study drug is dispensed following a negative pregnancy test
Understand the need and accept to undergo pregnancy testing based on the frequency outlined in this protocol
Females must agree to abstain from breastfeeding during study participation and for at least 28 days after study drug discontinuation
Males must agree to use a latex condom during any sexual contact with FCBP while participating in the study and for 90 days following discontinuation from this study, even if he has undergone a successful vasectomy
Males must also agree to refrain from donating semen or sperm while on the study drugs and for 90 days after discontinuation from this study treatment
Subjects must agree to refrain from donating blood while on study therapy and for 28 days after discontinuation from this study treatment
Subjects must agree not to share medication
Patients must meet the following clinical laboratory criteria
Absolute neutrophil count (ANC) 1 x 109/L
Platelet count 75 x 109/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells
Platelet count 30 x 109/L for patients in whom 50% of bone marrow nucleated cells are plasma cells. (Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment)
Total bilirubin 1.5 the upper limit of the normal range (ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 ULN
Calculated creatinine clearance 30 mL/min

Exclusion Criteria

Concomitant cancer chemo- or radiotherapy (except for local radiation therapy for preexisting lytic lesions)
Treatment with any investigational product within 60 days prior to first administration of pomalidomide and ixazomib
Patients eligible for autologous and / or allogeneic stem cell transplantation
Abnormal/inadequate organ or bone marrow function as defined below (any single parameter to fulfill condition): ANC < 1 x 109/L
Hemoglobin < 8.0 g/dL (prior RBC transfusion or recombinant human erythropoietin use is permitted)
Platelet count < 75 x 109/L for patients in whom < 50% of bone marrow nucleated cells are plasma cells
Platelet count < 30 x 109/L for patients in whom 50% of bone marrow nucleated cells are plasma cells
Estimated GFR (MDRD) < 45 ml/min
AST/ALT > 3 x upper limit of normal (ULN)
Serum (total) bilirubin > 1.5 x ULN
Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L); or free ionized calcium > 6.5 mg/dL (> 1.6 mmol/L)
Serum creatinine > 1.5 x ULN
Prior pomalidomide based therapy
Prior ixazomib based therapy
Baseline peripheral neuropathy > Grade 1 on clinical examination within 14 days before enrollment
Active HIV, hepatitis B (including patients who are tested Anti-HBc-positive and / or HBsAg-positive) or hepatitis C infection after serologic testing
Any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator
Known hypersensitivity to pomalidomide and its analogues in general and/or to ixazomib and its analogues or to any other component of study drugs
Prior malignancy excluding adequately treated with curative intent basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer without any evidence of residual disease or requiring anti-cancer treatment < 2 years prior to initiating study treatment
Patients with congestive heart failure NYHA Class III and IV, cardiac arrhythmias (except atrioventricular block type I and II, atrial fibrillation/flutter, bundle brunch block) or other signs and symptoms of relevant cardiovascular disease
Pregnant women, nursing mothers, lactating women, and women of childbearing potential as well as male subjects who are unwilling to adhere to the guidelines of the treatment-specific pregnancy prevention program
Unwilling or unable to follow protocol requirements
Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before randomization in the study
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of the study drugs including difficulty swallowing
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note